HOME >> BIOLOGY >> NEWS
New screening method turns up potential compound for treating anthrax

University of Chicago scientists have identified a compound that halts the activity of a deadly toxin called anthrax lethal factor in laboratory tests. Nature Biotechnology will publish the findings online on May 16 and in the June issue of the journal's print edition.

Anthrax lethal factor can only be effectively treated with antibiotics if administered soon after infection, making it difficult to treat patients who were unknowingly exposed to the bacterium. The Chicago research aims to develop a drug that could treat anthrax after antibiotics become ineffective.

The Chicago team discovered that a compound called DS-998 showed promising activity against anthrax lethal factor in cell cultures. Lethal factor is a molecule that chops up and renders inactive a protein that helps cells stay healthy. DS-998 blocks lethal factor's harmful cutting action.

The Chicago research is also the first time application of mass spectrometry to screen a library of compounds for medical applications. "We screened 10,000 compounds in three days. We estimate that it would be possible to screen 50,000 compounds a day with available robotic equipment," said Milan Mrksich, Professor in Chemistry at the University of Chicago. His co-authors of the Nature Biotechnology article are Dal-Hee Min, a Ph.D. student in chemistry, and Wei-Jen Tang, Associate Professor in the Ben May Institute for Cancer Research, both at the University of Chicago,

Rapid screening is an important component in making drug development more economical. It can cost a pharmaceutical company $250 million to develop a drug. Research and development alone can exceed $25 million, Mrksich said. "Typically hundreds of thousands of molecules are screened to identify 10 that are candidate drug leads," he said.

The search focused on small-molecule compounds. "In order to prevent the action of these toxins you need to have a molecule that is easily penetrable into the cell
'"/>

Contact: Steve Koppes
skoppes@uchicago.edu
773-702-8366
University of Chicago
16-May-2004


Page: 1 2

Related biology news :

1. March of Dimes statement on newborn screening report
2. Only 21 states offer newborn screening tests recommended by March of Dimes
3. Genetic screening study at Stanford IDs most aggressive adult leukemia strains
4. Genetic screening recommended to detect new neurodegenerative disorder in men over age 50
5. HPV testing could be future strategy for primary screening for cervical cancer
6. Newborn screening for certain genetic disorders has benefits and some drawbacks
7. SARS pre-screening protocol developed for AACR Annual Meeting in Washington, D.C.
8. UNC HIV-AIDS screening, prevention method could become national model for cutting illness
9. Study boosts confidence in potential screening tool for Alzheimers disease
10. Study: Prenatal screening in Haiti region cut syphilis by 75 percent
11. Study may help explain sunlights role in melanoma development, have screening implications

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/1/2020)... ... April 30, 2020 , ... ... announced today that it had been awarded a contract from the Biomedical Advanced ... for Preparedness and Response at the U.S. Department of Health and Human Services, ...
(Date:4/30/2020)... FREDERICA, Del. (PRWEB) , ... April 29, 2020 ... ... was well positioned for continued growth – delivering innovative solutions for a ... personal care, chemical, aerospace and government agencies. A month into the new decade, ...
(Date:4/23/2020)... ... April 23, 2020 , ... ... recruitment plans. MDG provides critical infrastructure products for the animal feed, human consumption, ... plans for expansion. Further, as supply channels from overseas competitors have become weakened ...
Breaking Biology News(10 mins):
(Date:5/15/2020)... ... May 14, 2020 , ... Children with defective heart ... before becoming adults. The reason: there are no heart valve prosthetics designed ... the Department of Defense has awarded Draper, Boston Children’s Hospital and Seattle Children’s ...
(Date:5/15/2020)... ... ... Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell ... will continue to lead Sentien’s Board of Directors, a role he has filled for ... Sentien’s management team. , Mr. Ganz has more than 30 years of ...
(Date:5/14/2020)... ... May 12, 2020 , ... NanoString Technologies , a ... of industry leaders, clinicians, research scientists, medical professionals and academics from around the ... Director of the Center for Cellular Immunotherapies at the Perelman School of Medicine ...
(Date:5/14/2020)... , ... May 13, 2020 , ... ... assays or phenotypic readouts, providing little or no information on the drug’s mechanism ... more comprehensive characterization of compounds by measuring the activity of molecular pathways. This ...
Breaking Biology Technology:
Cached News: